The ClariView Array is a uniquely designed microarray for patients with:
- Intellectual Disability (ID)
- Developmental Delay (DD)
- Autism Spectrum Disorder (ASD)
This array offers:
- Very high resolution in critical regions: detects exonic deletions and duplications as small as 1kb in 811 genes relevant to ID/ DD/ ASD, making this assay a first-line test for this group of patients.
- Increased probe coverage in known disease regions and around genes associated with specific Mendelian traits to detect changes ≥50 kb
- Backbone coverage in non-disease regions to detect changes ≥150 kb1
- 30,000 SNP probes are placed in the genome to detect AOH larger than 5-10 Mb2
Karyotype (chromosome analysis) and CMA generally should not be ordered at the same time. CMA is the first-tier test to screen for patients with non-specific intellectual disability/developmental delay (ID/DD), multiple congenital anomalies (MCA), and autism spectrum disorder (ASD). If the patient has features of a specific syndrome, it is generally better to test for that specific syndrome before ordering CMA.
If there are questions regarding this test, please contact Client Services at 617-553-5880 or email@example.com
Agilent 4x180k CMA
- The American College of Medical Genetics (ACMG) practice guidelines state that copy number variants ≥400 kb should be detectable by CMA.
- Single nucleotide polymorphisms (SNPs) are included as an additional means of determining CNVs, as well as a means of identifying stretches of areas of homozygosity (AOH). If there is copy neutral (no deletion or duplication) AOH, it indicates that there may be a shared common ancestor between the parents or uniparental disomy (UPD) of that region. It may also help to identify possible autosomal recessive conditions.